From the publishers of JADPRO

MPN Resource Center

Advertisement

Study of parsaclisib plus ruxolitinib in myelofibrosis discontinued

Last Updated: Tuesday, April 11, 2023

The phase 3 LIMBER-304 study of parsaclisib plus ruxolitinib in patients with myelofibrosis who had a previous suboptimal response to ruxolitinib alone has been discontinued, after a preplanned interim analysis determined that the trial was not expected to meet its primary endpoint of targeted reduction in spleen volume from baseline to week 24.

Targeted Oncology
Advertisement
News & Literature Highlights
Advertisement
Advertisement